Trastuzumab Emtansine

證據等級: L5

預測適應症: 4 個

Trastuzumab Emtansine: From HER2-Positive Breast Cancer to Progesterone-Receptor-Positive Breast Cancer

One-Sentence Summary

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate combining the anti-HER2 antibody trastuzumab with the cytotoxic microtubule inhibitor DM1, historically used in HER2-positive breast cancer. The TxGNN model predicts additional benefit in progesterone-receptor (PR) positive breast cancer, supported by 4 clinical trials and 15 publications — though as detailed below, this largely reflects an existing HER2+ subgroup rather than a genuinely novel indication.

Quick Overview

Item	Content
Original Indication	Not recorded in this evidence pack (formal `original_indications` field is empty — a data gap, not a true clinical blank; internal rationale text identifies HER2-positive breast cancer as the established use)
Predicted New Indication	Progesterone-receptor positive breast cancer
TxGNN Prediction Score	99.82%
Evidence Level	L1
Taiwan Market Status	Not marketed (0 licenses on file)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action documentation is a flagged data gap (DG002). Based on what is available in this evidence pack's own analysis, trastuzumab emtansine is an antibody-drug conjugate: the trastuzumab antibody component binds HER2-overexpressing tumor cells, delivering the conjugated payload DM1 (mertansine), a maytansinoid microtubule inhibitor, directly into the cell to induce cytotoxicity.

Critically, the evidence pack's own rationale flags an important caveat: PR status is a commonly co-existing biomarker in breast cancer, not an independent pharmacological target of T-DM1. The drug's activity is driven by HER2 expression, not PR status. This means the "PR-positive breast cancer" prediction substantially overlaps with the population already captured under the existing HER2-positive breast cancer indication — this is best understood as a biomarker-refined subgroup of an existing use, not a true novel repurposing signal.

Mechanistically, T-DM1 remains applicable wherever HER2 overexpression coexists with PR positivity (e.g., HR+/HER2+ disease), since PR status only informs whether concurrent endocrine therapy should be added — it does not change the drug's target engagement. Clinical selection should therefore continue to be anchored on HER2 status, with PR status used only as an adjunct for endocrine-therapy sequencing decisions.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03726879	Phase 3	Completed	454	IMpassion050: atezolizumab or placebo + neoadjuvant ddAC-paclitaxel-trastuzumab-pertuzumab in early HER2-positive breast cancer; strongest RCT-level evidence in this set (Grade A)
NCT02326974	Phase 2	Active, not recruiting	164	T-DM1 + pertuzumab in preoperative HER2-positive breast cancer, examining impact of HER2 heterogeneity on response
NCT06131424	N/A	Completed	1151	Retrospective, non-interventional study on HER2-low prevalence/characteristics in metastatic breast cancer; weak direct relevance (Grade C)
NCT04675827	Phase 2	Terminated	139	De-escalation of adjuvant chemotherapy in ER-negative, node-negative HER2+ early breast cancer after pCR; population is ER-negative, not PR-stratified (Grade C)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35640077	2022	Guideline	J Clin Oncol	ASCO guideline update on systemic therapy for HER2-positive advanced breast cancer
29939838	2018	Guideline	J Clin Oncol	ASCO clinical practice guideline update on systemic therapy for HER2-positive advanced breast cancer
24799465	2014	Review/Guideline	J Clin Oncol	Earlier ASCO practice guideline for HER2-positive advanced breast cancer systemic therapy
28259011	2017	Guideline/Review	Eur J Cancer	EGTM biomarker guideline noting HER2 (not PR alone) determines eligibility for anti-HER2 agents including T-DM1
33726508	2021	Review	Future Oncol	Reviews HR+/HER2+ breast cancer treatment trends, including T-DM1 in hormone-receptor co-positive disease
39631485	2024	Review	Pharmacol Res	Overview of targeted/cytotoxic breast cancer inhibitors, discussing HER2/HR/ER/PR-based treatment selection
35140078	2022	Case Report	BMJ Case Rep	Receptor conversion (biomarker status change) in breast cancer, illustrating limits of static PR/HER2 classification
35251981	2022	Case Report	Front Oncol	Leptomeningeal metastasis case in HER2-positive, PR-negative breast cancer treated with alternative anti-HER2 regimen
40642740	2025	Case Report	J Med Cases	Case of HER2-mutated triple-negative breast cancer responding to a related anti-HER2 ADC
37445276	2023	Preclinical	J Clin Med	In vitro study of an aminosteroid compound across breast cancer molecular subtypes, including PR-stratified subtypes

Taiwan Regulatory & Market Status

Trastuzumab emtansine is not currently marketed in this dataset — 0 authorizations on file, no license records available. No approved-indication text, product names, or dosage forms could be extracted.

Cytotoxicity

(Included because T-DM1 is an antibody-drug conjugate carrying a cytotoxic microtubule-inhibitor payload.)

Item	Content
Cytotoxicity Classification	Targeted therapy — antibody-drug conjugate (ADC); anti-HER2 antibody conjugated to DM1 (mertansine), a maytansinoid microtubule inhibitor cytotoxic payload
Myelosuppression Risk	Not available in this evidence pack — please refer to the package insert (blocked by data gap DG001)
Emetogenicity Classification	Not available in this evidence pack — please refer to the package insert (blocked by data gap DG001)
Monitoring Items	Not available in this evidence pack — please refer to the package insert (blocked by data gap DG001)
Handling Protection	Given the cytotoxic ADC payload, cytotoxic-drug handling precautions are likely warranted, but a formal handling protocol is not available in this evidence pack

Safety Considerations

Please refer to the package insert for safety information. All key warnings, contraindications, and drug-drug interaction data in this evidence pack are marked as unresolved data gaps (DG001, Blocking severity) — a TFDA package-insert review is required before any safety-related conclusions can be drawn.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The PR-positive breast cancer prediction is supported by one completed Phase 3 RCT (IMpassion050) and a body of ASCO/EGTM guideline literature, meeting L1 evidence criteria per the evidence pack's own scoring. However, this predicted indication substantially overlaps with the drug's already-established HER2-positive breast cancer use — PR status is a co-existing biomarker, not an independent target — so the "new indication" value here is limited, and safety data remain entirely unresolved.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain and parse the TFDA package insert for warnings/contraindications before any safety sign-off
Resolve DG002: obtain a formal, structured MOA record from DrugBank rather than relying on rationale-text mentions
Clarify the true original approved indication, since original_indications is empty despite this being a globally marketed drug — this gap should be closed before finalizing any "original → new indication" narrative
Confirm whether the PR+ subgroup adds any clinical decision-making value beyond existing HER2-status-based selection, or whether this prediction should be reclassified as confirmatory rather than novel
If Taiwan market entry is being considered, a full registration pathway assessment is required given 0 current licenses on file
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.